CN104884057B - 大麻素受体介导的化合物 - Google Patents

大麻素受体介导的化合物 Download PDF

Info

Publication number
CN104884057B
CN104884057B CN201380069389.9A CN201380069389A CN104884057B CN 104884057 B CN104884057 B CN 104884057B CN 201380069389 A CN201380069389 A CN 201380069389A CN 104884057 B CN104884057 B CN 104884057B
Authority
CN
China
Prior art keywords
alkyl
compound
optionally substituted
replaces
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380069389.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104884057A (zh
Inventor
G·库诺斯
M·艾耶
R·西纳
K·C·赖斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN104884057A publication Critical patent/CN104884057A/zh
Application granted granted Critical
Publication of CN104884057B publication Critical patent/CN104884057B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
CN201380069389.9A 2012-11-13 2013-11-12 大麻素受体介导的化合物 Active CN104884057B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725949P 2012-11-13 2012-11-13
US61/725,949 2012-11-13
PCT/US2013/069686 WO2014078309A1 (en) 2012-11-13 2013-11-12 Cannabinoid receptor mediating compounds

Publications (2)

Publication Number Publication Date
CN104884057A CN104884057A (zh) 2015-09-02
CN104884057B true CN104884057B (zh) 2019-08-20

Family

ID=49725346

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380069389.9A Active CN104884057B (zh) 2012-11-13 2013-11-12 大麻素受体介导的化合物

Country Status (7)

Country Link
US (6) US9765031B2 (enExample)
EP (1) EP2919779B1 (enExample)
JP (1) JP6272626B2 (enExample)
CN (1) CN104884057B (enExample)
CA (1) CA2889697C (enExample)
IN (1) IN2015DN03733A (enExample)
WO (1) WO2014078309A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2919779B1 (en) 2012-11-13 2021-01-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid receptor mediating compounds
US11155521B2 (en) * 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
WO2015172059A1 (en) * 2014-05-09 2015-11-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
US20180273485A1 (en) * 2015-06-04 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Cannabinoid receptor mediating compounds
EP3423448B1 (en) * 2016-03-04 2024-12-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid receptor mediating compounds
RU2703484C1 (ru) * 2018-05-22 2019-10-17 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" Способ производства безоболочных колбасок для функционального питания
WO2021189141A1 (en) * 2020-03-24 2021-09-30 Inversago Pharma Inc. Solid dispersions of amorphous 3, 4-diphenyl-4, 5-dihydro- 1h-pyrazole derivatives, compositions comprising them and uses thereof as cannabinoid cb1 receptor inhibitors
AU2021253263A1 (en) * 2020-04-07 2022-10-13 Novo Nordisk A/S Process for producing 4,5-dihydro-1H-pyrazoles and intermediates
EP4482490A4 (en) * 2022-02-24 2025-08-20 Novo Nordisk As METHODS OF TREATING SUBJECTS WITH HYPERTRIGLYCERIDEMIA, ABDOMINAL OBESITY AND/OR ALTERED GLUCOSE
EP4493547A1 (en) * 2022-03-14 2025-01-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Cannabinoid receptor modulating compounds
WO2025257151A1 (en) 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
IL151452A0 (en) * 2000-03-23 2003-04-10 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
CA2422708C (en) * 2001-03-22 2010-10-26 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
BR0208253A (pt) 2001-09-21 2004-04-13 Solvay Pharm Bv Compostos, composições farmacêuticas, método de preparação de composições farmacêuticas, processo para preparação de compostos, e, uso de um composto
KR100903760B1 (ko) * 2001-09-21 2009-06-19 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
PT1713475E (pt) 2004-01-30 2008-11-10 Solvay Pharm Bv Derivados de 4,5-diidro-1h-pirazol 1,3,5-trissubstituído tendo atividade antagonística a cb1
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2006060192A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives
CA2651385C (en) 2006-05-05 2015-02-03 John F. Mcelroy Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
US7655685B2 (en) 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
NZ585704A (en) 2007-12-10 2012-08-31 7Tm Pharma As Modulators of cannabinoid receptor CB1 for treating obesity
ES2540119T3 (es) 2009-03-27 2015-07-08 Abbvie Inc. Compuestos como ligandos de receptores cannabinoides
US8217038B2 (en) 2009-10-07 2012-07-10 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
CA2818198A1 (en) * 2010-11-18 2012-05-24 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
EP2919779B1 (en) * 2012-11-13 2021-01-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid receptor mediating compounds
US11155521B2 (en) * 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
WO2015172059A1 (en) 2014-05-09 2015-11-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
US20180273485A1 (en) * 2015-06-04 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Cannabinoid receptor mediating compounds

Also Published As

Publication number Publication date
US20230219896A1 (en) 2023-07-13
US20180022705A1 (en) 2018-01-25
CN104884057A (zh) 2015-09-02
CA2889697C (en) 2023-03-14
US20180022706A1 (en) 2018-01-25
US10683270B2 (en) 2020-06-16
EP2919779B1 (en) 2021-01-06
WO2014078309A1 (en) 2014-05-22
US10787419B2 (en) 2020-09-29
US20200331861A1 (en) 2020-10-22
US11485709B2 (en) 2022-11-01
US20160039766A1 (en) 2016-02-11
JP2015536997A (ja) 2015-12-24
CA2889697A1 (en) 2014-05-22
EP2919779A1 (en) 2015-09-23
WO2014078309A8 (en) 2015-05-21
IN2015DN03733A (enExample) 2015-09-18
US11939297B2 (en) 2024-03-26
US20230202983A1 (en) 2023-06-29
JP6272626B2 (ja) 2018-01-31
US9765031B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
CN104884057B (zh) 大麻素受体介导的化合物
US20190352268A1 (en) Cannabinoid receptor mediating compounds
JP6823095B2 (ja) 噴霧乾燥製剤
TW200845998A (en) Heterocyclic compounds useful in treating diseases and conditions
TW201625618A (zh) 抑制瞬時受體電位ａ１離子通道
AU2019227889B2 (en) Pyrazole derivatives and their use as cannabinoid receptor mediators
JP2022507117A (ja) 呼吸器疾患の処理のための新規な化合物
US20220144776A1 (en) Analogues of pentamidine and uses therefor
US11155521B2 (en) Cannabinoid receptor mediating compounds
EP3423448B1 (en) Cannabinoid receptor mediating compounds
US20250388542A1 (en) Analogues of pentamidine and uses therefor
HK1232213B (en) Pyrazole derivatives and their use as cannabinoid receptor mediators
TW200950782A (en) Therapeutic agent for cerebral infarction

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant